USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...
C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
In the latest trading session, C4 Therapeutics, Inc. (CCCC) closed at $6.51, marking a -1.96% move from the previous day.
Here is how AMN Healthcare Services (AMN) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
The consensus price target hints at a 227.3% upside potential for C4 Therapeutics, Inc. (CCCC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?